The Role of Adjuvant Radiation Therapy in the Treatment of Type B3 Thymoma

L. Gao,C. Wang,W. Fang,J. Zhang,C. Lv,S. Fu

DOI: https://doi.org/10.1016/j.ijrobp.2014.05.1691

2014-01-01

Abstract:To evaluate the long-term efficacy of adjuvant radiation therapy for the patients with type B3 thymoma. A total of 188 consecutive patients with type B3 (WHO) were treated from 2001 to 2010. 159 of them were enrolled into the analysis, 105 of the patients (66%) were received adjuvant radiation therapy (RT). A median age was 51 years (17–83 years). The distribution of Masaoka stages I, II, III, IVa and IVb was 35 (22%), 20 (12%), 73(46%), 28 (18%) and 3 (2%), respectively. MG coexisted in 34% of patients. All of patients underwent extended surgery and 72 % of patients received subsequent mediastinal adjuvant radiation therapy. After a mean follow-up of 49 months (7–135 months), the 10-year overall survival (OS) and disease-free survival (DFS) rates were 76 % (89%, 86 %,80% and 51% in stage I,II, III and IV, respectively) and 53% (100%,94%, 49 % and 12% in stage I, II, III and IV, respectively). There were no significant difference between the patients with or without adjuvant radiation therapy in terms of OS, DFS, FFR and TTP, but except median survival time (58.5 months for RT vs 45.3 months for no-RT patients, p = 0.01). In stratified analyses, the patients with Masaoka stage III+IV might be benefit from adjuvant radiation therapy, but not in multivariate analysis, only Masaoka stage is an independent prognostic factors for OS and FFR (freedom-from-recurrence), and resection status for TTP (time-to-progress). Adjuvant chemotherapy did not alter survival outcomes and recurrence patterns. Pleura was the most common recurrence site (24 patients, 69%). For the patients with type B3 thymoma, our primary analysis showed that adjuvant RT may increase median survival time and benefit to the patients with Masaoka stage III+IV, but not with stage I+II. Since most of the patients with Masaoka stage III+IV received adjuvant RT (83.6%), the role of adjuvant RT in the treatment of those patients is warrant to be further clarified in a prospective study.